ATC Group: N04B Dopaminergic agents

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N04B in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N04 Anti-parkinson drugs
3 N04B Dopaminergic agents

Group N04B contents

Code Title
N04BA Dopa and dopa derivatives
N04BB Adamantane derivatives
N04BC Dopamine agonists
N04BD Monoamine oxidase B inhibitors
N04BX Other dopaminergic agents

Active ingredients in N04B

Active Ingredient Description
Amantadine

Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.

Apomorphine

Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.

Bromocriptine

Bromocriptine is an inhibitor of prolactin secretion and a stimulator of dopamine receptors. The areas of application of bromocriptine are divided into endocrinological and neurological indications.

Cabergoline

Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity.

Dihydroergocryptine
Entacapone

Entacapone belongs to a new therapeutic class, catechol-O-methyl transferase (COMT) inhibitors. It is a reversible, specific, and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa preparations. Entacapone prolongs the clinical response to levodopa.

Levodopa

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.

Opicapone

Opicapone is a peripheral, selective and reversible catechol-O-methyltransferase (COMT) inhibitor endowed with a high binding affinity (sub-picomolar). Opicapone is indicated as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease, leading to an increase of levodopa plasma levels thereby improving the clinical response to levodopa.

Piribedil

Piribedil is a dopaminergic agonist (stimulates dopamine receptors and the cerebral dopaminergic pathways).

Pramipexole

Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.

Rasagiline

Rasagiline was shown to be a potent, irreversible MAO-B selective inhibitor, which may cause an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.

Ropinirole

Ropinirole is a non-ergoline D2/D3 dopamine agonist which stimulates striatal dopamine receptors. Ropinirole alleviates the dopamine deficiency which characterises Parkinson’s disease by stimulating striatal dopamine receptors.

Rotigotine

Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinson’s disease and Restless Legs Syndrome.

Safinamide

Safinamide acts through both dopaminergic and non-dopaminergic mechanisms of action. Safinamide is a highly selective and reversible MAO-B inhibitor causing an increase in extracellular levels of dopamine in the striatum. Safinamide is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as addon therapy to a stable dose of levodopa (L-dopa).

Selegiline

Selegiline is a selective MAO-B-inhibitor which prevents dopamine breakdown in the brain. It also inhibits the reuptake of dopamine at the presynaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous and endogenous dopamine. Thus, selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism.

Tolcapone

Tolcapone is an orally active, selective and reversible catechol-O-methyltransferase (COMT) inhibitor. Administered concomitantly with levodopa and an aromatic amino acid decarboxylase inhibitor (AADC-I), it leads to more stable plasma levels of levodopa by reducing metabolism of levodopa to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD). High levels of plasma 3-OMD have been associated with poor response to levodopa in Parkinson’s disease patients.

Related product monographs

Title Information Source Document Type  
ADARTREL Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
APO-GO Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BRAMESTON Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
CABASER Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
COMTAN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CORBILTA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
DACEPTON Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ELDEPRYL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
INBRIJA Inhalation powder, capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
KYNMOBI Sublingual film FDA, National Drug Code (US) MPI, US: SPL/PLR
LEVOMED Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MADOPAR Capsule, Rapid dispersible tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
MEDAPIA Film-coated tablet Medicines Authority (MT) MPI, EU: SmPC
MIRAPEX Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
MIRAPEXIN Tablet / Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
NEUPRO 1mg/24h, 3mg/24h Transdermal patch European Medicines Agency (EU) MPI, EU: SmPC
NEUPRO 2mg/24h Transdermal patch European Medicines Agency (EU) MPI, EU: SmPC
NEUPRO 4mg/24h, 6mg/24h, 8mg/24h Transdermal patch European Medicines Agency (EU) MPI, EU: SmPC
ONGENTYS Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
ONTILYV Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
PARLODEL Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RASAGILINE MYLAN Tablet European Medicines Agency (EU) MPI, EU: SmPC
ROLPRYNA Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
ROPIQUAL XL Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SELEGOS Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
SIFROL Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
SIFROL Tablet European Medicines Agency (EU) MPI, EU: SmPC
STALEVO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
Symmetrel Capsules Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TASMAR Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TRIVASTAL Sustained release coated tablet Web Search MPI, EU: SmPC
XADAGO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC